RheumNow Podcast – ACR Convergence Begins (11.5.2021) Save

Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting.

1. Study 144 pts Rx w/ Rituximab for Autoimmune renal Dz (AAV, FSGS, IgG4RD, LN, etc). 17% had Severe infections (SIE) w/in 3 mos; mostly pulm & GU. Risk factors=BMI, high creatinine. Hypogammaglobulinemia was frequent (58.5%) but not associated with SIE https://t.co/2jaxC4xLhc

2. Early RA cohort (CATCH) 1891 early RA, 30% Rx oral steroids as bridge therapy; but 30% of these did not taper or D/C steroids after 24 mos. Early GC use assoc w/ age, unemployment, high Dz activity, later biologic use.https://t.co/dva1A6QHAk

3. Systematic review of dietary interventions for RA - 30 RCTs, 1063 pts; Pain was most reported outcome, sporadic studies showed occ. lowering of ESR, CRP, TNF, Plts, Igs, etc. Few studies show Anti-inflammatory diets may effective lowering DAS in RAhttps://t.co/B46NrVkwcK

4. Serologically Active, Clinically Quiescent SLE

5. 2 inactive (86%) #RA pts were treated with checkpoint inhibitors & Immune-related adverse events occurred in 7 (32%; two severe AE) leading to 6/22 D/C. RA flares occurred in 12 (55%); 10/12 Rx with steroids & good response. https://t.co/zemGVZOnYL

6. Management of Immune-Related Adverse Events - ASCO Guideline 

7. RheumNowS ACR21 Coverage